CheckMate 9LA: 2-Yr Update of First-line Nivolumab + Ipilimumab With 2 Cycles of Chemotherapy vs Chemotherapy Alone in Advanced NSCLC

June 4-8, 2021; Online at https://conferences.asco.org/am
First-line nivolumab plus ipilimumab with chemotherapy continued to provide durable clinical benefit in patients with advanced NSCLC regardless of PD-L1 expression with extended follow-up.
Format: Microsoft PowerPoint (.ppt)
File Size: 562 KB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

On-demand webcast from CCO where clinical experts discuss how to optimally integrate the latest clinical data on predictive biomarkers to guide treatment decisions in advanced NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO
Program Director
Stephen V. Liu, MD Lecia V. Sequist, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 26, 2021 Expired: July 25, 2022

In this on-demand webcast from CCO, Mary Jo Fidler, MD, and Scott Gettinger, MD, review the latest advances in immunotherapy for NSCLC through discussion of a series of patient cases.

person default Mary Jo Fidler, MD person default Scott Gettinger, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 15, 2021 Expired: July 14, 2022

Download this short slideset for an overview of the current status of biomarkers guiding optimal use of targeted therapy and immunotherapy in the treatment of advanced NSCLC, from CCO

Stephen V. Liu, MD Suresh S. Ramalingam, MD, FACP, FASCO Lecia V. Sequist, MD, MPH Released: July 8, 2021

Video from Clinical Care Options (CCO) featuring latest guidance in the diagnosis and treatment of patients with NTRK fusion positive cancers.

George D. Demetri, MD
Program Director
Alexander Drilon, MD Theodore Laetsch, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 7, 2021 Expired: July 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue